Study GLP111892: Albiglutide Versus Placebo as Add-on to Intensified Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus
Status: Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 28 Jan 2016
Price : $35 *
At a glance
- Drugs Albiglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms GLP111892
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 08 Jan 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 11 May 2015 Planned initiation date changed from 1 Oct 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov record.